KALV NASDAQ
KalVista Pharmaceuticals, Inc.
1W: +0.2%
1M: +0.8%
3M: +59.4%
YTD: +74.6%
1Y: +100.6%
3Y: +173.3%
5Y: -3.9%
$27.00
Last traded 2026-06-12 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2024-11-04
Earliest Filing
2025-04-08
Latest Filing
partner: 4
investor: 2
Counterparties (Filed by KALV)
6 relationshipsCompanies named in KALV's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Kaken Pharmaceutical Co., Ltd | — | partner | License, Supply, and Distribution Agreement for commercialization rights in Japan of sebetralstat | 2025-04-08 | View |
| DRI Healthcare Acquisitions LP | — | investor | Purchased revenue participation rights for sebetralstat sales | 2024-11-04 | View |
| DRI Healthcare Trust | — | partner | Affiliate of the purchaser DRI Healthcare Acquisitions LP | 2024-11-04 | View |
| Jefferies LLC | JEF | partner | Underwriter for the common stock offering | 2024-11-04 | View |
| Stifel Nicolaus & Company, Incorporated | — | partner | Underwriter for the common stock offering | 2024-11-04 | View |
| DRI Healthcare Acquisitions LP | — | investor | Purchaser of private placement shares | 2024-11-04 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-06-11 | Material Agreement; Termination of Agreement; Acquisition/Disposition; Financial Obligation; Delisti | Agreement Acquisition | View |
| 2026-04-29 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-03-25 | Earnings Release; Exhibits | View | |
| 2026-01-08 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-06 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-10-02 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-09-29 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-09-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-21 | Other Events | View | |
| 2025-07-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-07 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-12 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-04-08 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-03-17 | Amendments to Articles of Incorporation or Bylaws | View | |
| 2025-03-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-12-16 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2024-12-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-26 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2024-11-04 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Regulation FD Dis | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR